KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nu Skin Enterprises (NUS) Cash & Equivalents (2016 - 2025)

Nu Skin Enterprises' Cash & Equivalents history spans 17 years, with the latest figure at $238.6 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 27.69% year-over-year to $238.6 million; the TTM value through Dec 2025 reached $238.6 million, up 27.69%, while the annual FY2025 figure was $238.6 million, 27.69% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $238.6 million at Nu Skin Enterprises, down from $251.8 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $363.9 million in Q2 2022 and bottomed at $186.9 million in Q4 2024.
  • The 5-year median for Cash & Equivalents is $253.9 million (2023), against an average of $265.3 million.
  • The largest annual shift saw Cash & Equivalents tumbled 35.27% in 2023 before it grew 27.69% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $339.6 million in 2021, then decreased by 22.05% to $264.7 million in 2022, then fell by 3.27% to $256.1 million in 2023, then decreased by 27.02% to $186.9 million in 2024, then increased by 27.69% to $238.6 million in 2025.
  • Per Business Quant, the three most recent readings for NUS's Cash & Equivalents are $238.6 million (Q4 2025), $251.8 million (Q3 2025), and $264.2 million (Q2 2025).